Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Chronically radiation-exposed survivor GBM cells display poor response to Chk1 inhibition.

ABSTRACT: Chronically radiation-exposed survivor GBM cells display poor response to Chk1 inhibition.

PROVIDER: PRJNA821847 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18559254.fastq.gz	Fastqsanger.gz
	SRR18559255.fastq.gz	Fastqsanger.gz
	SRR18559256.fastq.gz	Fastqsanger.gz
	SRR18559257.fastq.gz	Fastqsanger.gz
	SRR18559258.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Chronically radiation-exposed survivor GBM cells display poor response to Chk1 inhibition.

Project description:To investigate radiation response of reccurent glioblastoma models after radiotherapy, we have utilized clinically relevant radioresistant cell model. We have generated to radiation survivor GBM population from 1 cell line and 1 primary cell line. To investigate transcriptomic alterations we have performed RNA-seq to our both naive and IR survivor samples as triplicates.

2022-07-13 | GSE199862 | GEO

Chronically Radiation-Exposed Survivor Glioblastoma Cells Display Poor Response to Chk1 Inhibition under Hypoxia.

Project description:Glioblastoma is the most malignant primary brain tumor, and a cornerstone in its treatment is radiotherapy. However, tumor cells surviving after irradiation indicates treatment failure; therefore, better understanding of the mechanisms regulating radiotherapy response is of utmost importance. In this study, we generated clinically relevant irradiation-exposed models by applying fractionated radiotherapy over a long time and selecting irradiation-survivor (IR-Surv) glioblastoma cells. We examined the transcriptomic alterations, cell cycle and growth rate changes and responses to secondary radiotherapy and DNA damage response (DDR) modulators. Accordingly, IR-Surv cells exhibited slower growth and partly retained their ability to resist secondary irradiation. Concomitantly, IR-Surv cells upregulated the expression of DDR-related genes, such as CHK1, ATM, ATR, and MGMT, and had better DNA repair capacity. IR-Surv cells displayed downregulation of hypoxic signature and lower induction of hypoxia target genes, compared to naïve glioblastoma cells. Moreover, Chk1 inhibition alone or in combination with irradiation significantly reduced cell viability in both naïve and IR-Surv cells. However, IR-Surv cells' response to Chk1 inhibition markedly decreased under hypoxic conditions. Taken together, we demonstrate the utility of combining DDR inhibitors and irradiation as a successful approach for both naïve and IR-Surv glioblastoma cells as long as cells are refrained from hypoxic conditions.

| S-EPMC9266388 | biostudies-literature

CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress

Project description:While effective anti-cancer drugs targeting the CHK1 kinase are advancing in the clinic, drug resistance is rapidly emerging. Here, we demonstrate that CRISPR-mediated knockout of the little-known gene FAM122A confers cellular resistance to CHK1 inhibitors and cross-resistance to ATR inhibitors. Knockout of FAM122A results in activation of PP2A-B55α, a phosphatase which dephosphorylates the WEE1 protein and rescues WEE1 from Ubiquitin-mediated degradation. The resulting increase in WEE1 protein expression reduces replication stress, activates the G2/M checkpoint, and confers cellular resistance to CHK1 inhibitors. Interestingly, in tumor cells with oncogene-driven replication stress, CHK1 can directly phosphorylate FAM122A, leading to activation of the PP2A-B55α phosphatase and increased WEE1 expression. A combination of a CHK1 inhibitor plus a WEE1 inhibitor can overcome CHK1 inhibitor resistance of these tumor cells, thereby enhancing anti-cancer activity. The FAM122A expression level in a tumor cell can serve as a useful biomarker for predicting CHK1 inhibitor sensitivity or resistance.

2021-01-01 | GSE158338 | GEO

CHK1 inhibition following gemcitabine treatment

Project description:CHK1 inhibition following gemcitabine treatment

| PRJNA262182 | ENA

Phosphoproteomics analysis of CHK1 inhibitor treatment

Project description:Inhibitors of checkpoint kinase 1 (CHK1),a central component of DNA damage and cell cycle checkpoint response, represent a promising new cancer therapy, but the global cellular functionsthey regulate through phosphorylationare poorly understood. To elucidate the CHK1-regulated phosphorylation network, we performed a global quantitative phosphoproteomics analysis, which revealed 142 phosphositeswhose phosphorylation levels were significantly different following treatment with the CHK1 inhibitor SCH 900776.

2020-04-23 | PXD015125 | Pride

Transcriptomic analysis of pre- and post-treatment GBM tumors (GBM-28 vs. GBM-37)

Project description:Transcriptomic analysis of pre- and post-treatment GBM tumors (GBM-28 vs. GBM-37)

| PRJNA666454 | ENA

GBM brain tumors

Project description:This SuperSeries is composed of the following subset Series: GSE24446: Genetic abnormalities in GBM brain tumors GSE24452: Genetic abnormalities in various cell subpopulations of GBM brain tumors GSE24557: Exon-level expression profiles of GBM brain tumors Refer to individual Series

2010-11-21 | E-GEOD-24558 | biostudies-arrayexpress

The phosphoproteomics study of Chk1 and ATR inhibitors regulation on cells

Project description:Ataxia Telangiectasia and Rad3-related (ATR) and Checkpoint Kinase 1 (Chk1) are crucial kinases in the DNA Damage Response (DDR) pathway. While the roles of ATR and Chk1 within the DDR are well-established, their roles in mitosis are not fully understood. Here, we describe that the ATR-Chk1 pathway is rewired in mitosis to promote full CDK1 activity, a stark contrast to their role in interphase to inhibit CDK1 following DNA damage. We use mass spectrometry validated the phosphorylation changes after the treatment of ATR and Chk1 inhibitors and confirmed in vitro that Chk1 inhibits residual activity of PKMYT1 (Myt1) via direct phosphorylation at Serine 143.

2025-06-23 | PXD058541 | Pride

Identification of DNA methylation signatures associated with poor outcome in lower-risk Stage, Size, Grade and Necrosis (SSIGN) score clear cell renal cell cancer

Project description:DNA methylation from LTS (long term survivor) and STS (short term survivor) kidney tumors

2021-01-19 | GSE150402 | GEO

Expression data of CHK1 shRNA knockdown and control shRNA in U2OS cells

Project description:Homologous recombination-mediated DNA repair deficiency (HRD) predisposes to cancer development, but also provides therapeutic opportunities. Here, we identified an HRD gene signature that robustly predicted HRD status. Unexpectedly, concurrent loss of PTEN in BRCA1-deficient cells might extensively rewire the HR repair network and confer resistance to PARP inhibitor, partially through over-expression of TTK. We used the HRD gene signature as a drug discovery tool and found several PARP-inhibitor-synergizing agents through the connectivity map. Thus gene expression profiling can be used to define the functional status of the HR repair network providing prognostic and therapeutic information. Various shRNAs that target genes involved in homologous recombination (HR) were transfected in MCF-10A non-transformed breast cells lines. Stable HR gene knockdown MCF-10A cells were seeded 200000 at 10 cm plate. Cells were harvested after 48 hours culturing and used for gene expression profiling. The shRNA that target CHK1 gene was transfected in human osteosarcoma U2OS cell line by lentiviral particles and selected stable CHK1 knockdown U2OS cells. Scrambled control shRNA-transfected U2OS cells were applying as control. Both stable CHK1 knockdown and control U2OS cells were seeded with 2 x 10^5 cells at 10 cm culture plate. Cells were cultured in McCOY 5A medium with 10% FBS and harvested after 48 hours culturing. mRNA was extracted from collected cells and performing gene expression profiling. Three biological replicates were applied.

2014-01-24 | E-GEOD-54267 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data